AU9278598A - Use of azole derivatives for the treatment of inflammatory skin conditions - Google Patents

Use of azole derivatives for the treatment of inflammatory skin conditions

Info

Publication number
AU9278598A
AU9278598A AU92785/98A AU9278598A AU9278598A AU 9278598 A AU9278598 A AU 9278598A AU 92785/98 A AU92785/98 A AU 92785/98A AU 9278598 A AU9278598 A AU 9278598A AU 9278598 A AU9278598 A AU 9278598A
Authority
AU
Australia
Prior art keywords
treatment
skin conditions
inflammatory skin
azole derivatives
azole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU92785/98A
Inventor
Dominique Castelli
Gerd Ries
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson and Johnson Consumer Holdings France SAS
Original Assignee
Roc AG
Roc SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roc AG, Roc SA filed Critical Roc AG
Publication of AU9278598A publication Critical patent/AU9278598A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
AU92785/98A 1997-10-16 1998-10-15 Use of azole derivatives for the treatment of inflammatory skin conditions Abandoned AU9278598A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9712951A FR2769838B1 (en) 1997-10-16 1997-10-16 USE OF NITROGEN DERIVATIVES FOR THE PREPARATION OF A DERMATOLOGICAL OR COSMETOLOGICAL COMPOSITION
FR9712951 1997-10-16
PCT/IB1998/001617 WO1999020271A1 (en) 1997-10-16 1998-10-15 Use of azole derivatives for the treatment of inflammatory skin conditions

Publications (1)

Publication Number Publication Date
AU9278598A true AU9278598A (en) 1999-05-10

Family

ID=9512294

Family Applications (1)

Application Number Title Priority Date Filing Date
AU92785/98A Abandoned AU9278598A (en) 1997-10-16 1998-10-15 Use of azole derivatives for the treatment of inflammatory skin conditions

Country Status (4)

Country Link
AU (1) AU9278598A (en)
CO (1) CO4970838A1 (en)
FR (1) FR2769838B1 (en)
WO (1) WO1999020271A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19938404A1 (en) * 1999-08-13 2001-02-22 Clariant Gmbh Cosmetic preparations
US20050201965A1 (en) * 2004-03-11 2005-09-15 The Procter & Gamble Company Personal cleansing compositions
CA2572223C (en) 2004-06-25 2014-08-12 The Johns Hopkins University Angiogenesis inhibitors
US20060142304A1 (en) * 2004-12-27 2006-06-29 Michael Southall Method for treating or preventing pruritic and neurogenic skin disorders
EP2906946A1 (en) 2012-10-09 2015-08-19 The Procter & Gamble Company Method of identifying or evaluating beneficial actives and compositions containing the same
WO2014059009A1 (en) 2012-10-09 2014-04-17 The Procter & Gamble Company Method of identifying synergistic cosmetic combinations
US9144538B2 (en) 2013-02-08 2015-09-29 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for alleviating the signs of photoaged skin
US9138393B2 (en) 2013-02-08 2015-09-22 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for improving the appearance of aging skin
EP3897624A1 (en) * 2018-12-17 2021-10-27 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of sulconazole as a furin inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210840A (en) * 1984-01-18 1987-05-29 Johnson & Johnson Baby Prod Composition comprising synergistic combination of miconazole nitrate and zinc oxide
ZA887662B (en) * 1987-10-19 1989-06-28 Merrell Dow Pharma Method for reducing reperfusion injury with imidazol-2-thione-carboxamides
FR2711990B1 (en) * 1993-11-05 1995-12-08 Exsymol Sa Pseudodipeptide product having an imidazole group, and therapeutic, cosmetological and agrifood applications.
FR2714380B1 (en) * 1993-12-24 1996-05-24 Bioxytech Use of 2-mercapto-imidazole derivatives substituted in position 4 (or 5) as antioxidants, their preparation process and their applications in pharmacy, cosmetics or food.

Also Published As

Publication number Publication date
WO1999020271A1 (en) 1999-04-29
FR2769838A1 (en) 1999-04-23
FR2769838B1 (en) 2000-04-07
CO4970838A1 (en) 2000-11-07

Similar Documents

Publication Publication Date Title
AU3548795A (en) Benzopyranopyrazolyl derivatives for the treatment of inflammation
AU3201095A (en) Substituted thiazoles for the treatment of inflammation
IL132296A0 (en) Substituted benzopyran derivatives for the treatment of inflammation
AU3441197A (en) 3-ureido-pyridofurans and -pyridothiophenes for the treatment of inflammatory processes
IL132318A0 (en) Substituted imidazoles useful in the treatment of inflammatory diseases
AU2766097A (en) Acyl mercapto-triazolyl derivatives and the use thereof as microbicides
AUPP609198A0 (en) Use of non-peptidyl compounds for the treatment of insulin related ailments
AU2039800A (en) 5-membered heterocycles for the treatment of human diseases involving modulatorsof selectins
AU2228297A (en) Use of isoniazid for the treatment of hyperlipoproteinemia
HU9802971D0 (en) The use of mmp inhibitors for the treatments of ocular angiogenesis
AU2424895A (en) Substituted spirodienes for the treatment of inflammation
AU4774597A (en) Use of 1-hydroxy-2-pyridones for the treatment of skin infections
AU2199195A (en) Fungicidal azole derivatives
AU5056099A (en) Compounds for use in the treatment of inflammation
AU9278598A (en) Use of azole derivatives for the treatment of inflammatory skin conditions
AU3187595A (en) Compounds for the treatment of restenosis
AU7310896A (en) Use of nitroflavonoids for the treatment of anxiety
AU2021601A (en) Composition for the treatment of dandruff
AU1878201A (en) Composition for the treatment of damaged tissue
AU3814599A (en) Use of erythropoietin for the treatment of haemochromatoses
AU4712696A (en) The use of heterocyclic compounds
AU7653600A (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis
AU5699396A (en) Compositions for the treatment of skin conditions
IL130831A0 (en) Imino-aza-anthracylinone derivatives for the treatment of amyloidosis
AU1940800A (en) Combination therapy for the treatment of sepsis

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase